Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Ovarian Cancer
Interventions
Cryopreservation of gonadal tissue
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 30 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Turner's Syndrome
Interventions
growth hormone, oxandrolone
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
10 Years to 14 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Turner Syndrome, Primary Ovarian Insufficiency (Poi)
Interventions
Micronized progesterone 200 MG, Micronized Progesterone 100 MG
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 20 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Turner Syndrome
Interventions
Research genetic tests
Genetic
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Female only
Enrollment
200 participants
Timeline
2015 – 2035
U.S. locations
1
States / cities
Houston, Texas
Conditions
SGA, Turner Syndrome, Noonan Syndrome, ISS
Interventions
Somapacitan
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Sacramento, California • Centennial, Colorado + 3 more
Completed No phase listed Observational Accepts healthy volunteers

Turner Syndrome: Genotype and Phenotype

NCT00006334
Conditions
Turner's Syndrome
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
10 Years and older
Enrollment
1,017 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes

NCT02213484
Conditions
Marfan Syndrome, Loeys-Dietz Syndrome, Thoracic Aortic Aneurysm and Dissection Syndromes, Ehlers-Danlos Type IV Syndrome, Turner Syndrome
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Days to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Aurora, Colorado
Conditions
Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions
17 beta estradiol
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
10 Years to 16 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Turner Syndrome
Interventions
somatotropin
Drug
Lead sponsor
Rebecca Knickmeyer Santelli, PhD
Other
Eligibility
11 Months to 13 Months · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Terminated No phase listed Observational Accepts healthy volunteers

Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial

NCT01545674
Conditions
Trisomy 13, Trisomy 18, Trisomy 21, Aneuploidy
Interventions
Blood Draw
Procedure
Lead sponsor
Natera, Inc.
Industry
Eligibility
Female only
Enrollment
937 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 16 more
Recruiting No phase listed Observational

Turner Syndrome: Genetic Considerations

NCT07502586
Conditions
Genetic
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Day to 110 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hypothalamic Obesity
Interventions
Bivamelagon
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Aurora, Colorado • Iowa City, Iowa • Boston, Massachusetts + 3 more
Conditions
Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis, Idiopathic Non-Cirrhotic Portal Hypertension
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Accepts healthy volunteers

The Effects of Estrogen on Cognition in Girls With Turner Syndrome

NCT00001253
Conditions
Gonadal Dysgenesis, Turner's Syndrome
Interventions
cognitive tests and scales
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1990 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Active, not recruiting No phase listed Observational

Pathogenetic Basis of Aortopathy and Aortic Valve Disease

NCT03440697
Conditions
Aortopathies, Thoracic Aortic Aneurysm, Aortic Valve Disease, Thoracic Aortic Disease, Thoracic Aortic Dissection, Thoracic Aortic Rupture, Ascending Aortic Disease, Descending Aortic Disease, Ascending Aortic Aneurysm, Descending Aortic Aneurysm, Marfan Syndrome, Loeys-Dietz Syndrome, Vascular Ehlers-Danlos Syndrome, Shprintzen-Goldberg Syndrome, Turner Syndrome, PHACE Syndrome, Autosomal Recessive Cutis Laxa, Congenital Contractural Arachnodactyly, Arterial Tortuosity Syndrome, Bicuspid Aortic Valve-Associated Aortopathy, Bicuspid Aortic Valve, Familial Thoracic Aortic Aneurysm and Aortic Dissection
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
2
States / cities
Atlanta, Georgia • Indianapolis, Indiana
Completed Phase 1Phase 2 Interventional Results available

Effects of Exenatide on Hypothalamic Obesity

NCT01061775
Conditions
Hypothalamic Obesity
Interventions
Exenatide
Drug
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
10 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Orange, California • Saint Paul, Minnesota
Conditions
Turner's Syndrome
Interventions
Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch
Drug
Lead sponsor
University of Chicago
Other
Eligibility
138 Months to 13 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan
Conditions
Trisomy 21, Trisomy 18, Trisomy 13, Monosomy X
Interventions
Not listed
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Microdeletion Syndromes, Trisomy 21, Trisomy 18, Trisomy 13, Sex Chromosome Abnormalities
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
Not listed
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
San Carlos, California • Philadelphia, Pennsylvania
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism

NCT00837616
Conditions
Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions
17 B estradiol orally, 17 B estradiol
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 20 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Jacksonville, Florida • Philadelphia, Pennsylvania
Not listed No phase listed Observational Accepts healthy volunteers

Whole Blood Specimen Collection From Pregnant Subjects

NCT02430584
Conditions
Down Syndrome, Edwards Syndrome, Patau Syndrome, Klinefelter Syndrome, Turner Syndrome, DiGeorge Syndrome, Perinatal Infections
Interventions
Observational - no intervention
Other
Lead sponsor
Progenity, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Chattanooga, Tennessee
Conditions
Turner Syndrome
Interventions
estrogen, androgen, placebo
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
10 Years to 14 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2012
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Conditions
Gonadal Dysgenesis, Turner's Syndrome
Interventions
Growth Hormone (Humatrope)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Turner Syndrome
Interventions
Somatropin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
9 Months to 4 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
10
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 7 more